

Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

Information for the public

Published: 1 February 2023

www.nice.org.uk

Nintedanib (Ofev) is available on the NHS as a possible treatment for idiopathic pulmonary fibrosis in adults if their forced vital capacity is above 80% of the value expected for them. Idiopathic means we do not know what is causing the pulmonary fibrosis.

If you are not eligible for nintedanib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Action for Pulmonary Fibrosis](#), 01223 785725
- [Asthma & Lung UK](#), 0300 222 5800

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4986-1